AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) showcased promising developments in the use of its investigational drug Ampligen for treating late-stage pancreatic cancer at the 5th Annual Marie Sk?odowska-Curie Symposium in Poland. CEO Thomas K. Equels presented compelling data indicating improvements in both Progression-Free Survival (PFS) and Overall Survival (OS) from the ongoing Phase 2 DURIPANC clinical trial and an Early Access Program.
Ampligen, an innovative dual-stranded RNA and TLR3 agonist, is currently being evaluated in combination with AstraZeneca's durvalumab, an anti-PD-L1 inhibitor, under ClinicalTrials.gov identifier NCT05927142. This combination aims to enhance treatment outcomes for patients with late-stage metastatic pancreatic cancer, a condition with high unmet medical needs. Equels emphasized the significance of the results thus far, stating that the sustained positive data strengthens their confidence in Ampligen’s transformative potential in this challenging therapeutic area.
The presentation underscores AIM ImmunoTech's commitment to advancing Ampligen’s development. The drug is protected by U.S. patents until 2039 and has received orphan drug designations in both the U.S. and EU, ensuring market advantages upon successful approval. With the ongoing clinical studies, AIM aims to address the critical needs of pancreatic cancer patients who currently face limited therapeutic options.
For further information and updates on Ampligen, AIM encourages interested parties to visit their website. Despite the encouraging data, the company cautions investors regarding the uncertainties associated with drug approval processes, reminding them to consider the associated risks as outlined in their SEC filings.
For more details, please refer to the company’s website and recent updates.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) has garnered attention following its recent presentation at the Fifth Annual Marie Sk?odowska-Curie Symposium on Cancer Research and Care in Poland, where the potential of its lead product, Ampligen, for treating pancreatic cancer was showcased. The data from the ongoing Phase 2 DURIPANC clinical trial and the Early Access Program indicate promising outcomes in terms of Progression-Free Survival (PFS) and Overall Survival (OS), core metrics that are crucial for further drug development and regulatory approvals.
The necessity for innovative treatments in pancreatic cancer is substantial, given the high unmet medical need and poor prognosis associated with this disease. Ampligen’s positive claims in trials could position AIM as a key player in the oncology space, especially if the drug can secure approvals under its patent protection, which extends through 2039 in the U.S. Additionally, the orphan drug designation offers a competitive edge by providing market exclusivity once approved.
While the positive interim results warrant optimism, investors should approach the stock with caution. The path to FDA approval is fraught with challenges, and previous clinical data does not guarantee future success. The volatility commonly associated with biotechnology stocks can pose risks, and investors must be prepared for potential fluctuations as further results from ongoing studies emerge.
In summary, AIM ImmunoTech demonstrates a compelling narrative around Ampligen that could appeal to investors interested in biotech opportunities. Given the promising data and unmet needs in pancreatic cancer, AIM may present a speculative buy or hold for cautious investors, especially as more robust clinical trial results materialize. Keeping abreast of future announcements will be essential for assessing the company’s growth trajectory and market potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Sk?odowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here
Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program
OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the presentation on the latest positive progress from its Ampligen clinical program in pancreatic cancer at the 5 th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care hosted by and at Poland’s National Institute of Oncology in Warsaw, Poland.
AIM CEO Thomas K. Equels provided an overview of data from AIM’s pancreatic cancer Early Access Program and the latest advancements in the Phase 2 DURIPANC pancreatic cancer clinical trial currently underway at Erasmus University Medical Center in the Netherlands. The slides accompanying the presentation are now available on the Company’s website .
“Ampligen continues to demonstrate its potential for the treatment of late-stage metastatic and locally advanced pancreatic cancer. Our growing body of positive data continues to bolster our confidence. This lethal malignancy is a high unmet need. In particular, the Progression-Free Survival and Overall Survival – which are the gold standards for drug approval – seen in the clinical data demonstrated to date underscore our strong belief in the potential,” AIM ImmunoTech CEO Thomas K. Equels stated. “I am pleased to be a part of this gathering of global regulatory leaders, world-renowned oncologists and biopharma industry to share this important progress with Ampligen and highlight its potential in late-stage pancreatic cancer. We look forward to advancing its development and remain committed to bringing it to patients in desperate need and without real hope.”
AIM’s drug Ampligen is currently being tested in an ongoing Phase 2 DURIPANC clinical study evaluating the combination therapy of Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor durvalumab in the treatment of late-stage metastatic pancreatic cancer patients (See: ClinicalTrials.gov NCT05927142 ). Ampligen has patent protection for such a combination therapy in the United States through 2039, and US and EU orphan drug designations that will grant market protections for an approved drug.
For more information on Ampligen and to stay up to date with the latest advancements, please visit the Company’s website, aimimmuno.com .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5084607c-f35a-48da-8b06-10fa35de54ff
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
What specific data metrics from the DURIPANC clinical trial and Early Access Program support AIM ImmunoTech Inc. AIM's claims about Ampligen's potential efficacy in improving Progression-Free Survival and Overall Survival for pancreatic cancer patients?
Can AIM ImmunoTech Inc. AIM provide insights into the next steps in the clinical development of Ampligen, especially regarding regulatory approvals and timelines following the promising results presented at the Symposium?
How does AIM ImmunoTech Inc. AIM plan to address the challenges and risks associated with the commercial development of Ampligen, given the significant unmet need in treating late-stage pancreatic cancer?
What are the expected competitive advantages of Ampligen over existing treatments for pancreatic cancer, and how does AIM ImmunoTech Inc. AIM differentiate its product in a crowded immunotherapy landscape?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
